Trial
NCT04408755
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Agitation in Patients With Dementia of the Alzheimer's Type
Intervention
AVP-786
Why stopped
The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-30